Page 2 - Gijs Klarenbeek News Today : Breaking News, Live Updates & Top Stories | Vimarsana

            POSEIDON – positive interim results in Q4 2020; additional interim results expected in Q2 2021 and primary endpoint in Q2 2022 RED DESERT – positive interim results in Q4 2020; top-line data expected in Q2 2021 Successful equity placements extend cash runway into Q2 2022 Conference call with live Ghent, BELGIUM – 17 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended 31 December 2020, and provides a business update and an outlook for the remainder of 2021. Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “We made outstanding progress in 2020, delivering very promising clinical data in both our focus areas, liver disease / NASH

United statesJames udelsonPeter dhondtCian crosbieGijs klarenbeekMichael felkerGuillaume van renterghemInformation technologyYale university school of medicineSequana medicalYear resultsEuronext brusselsChief executive officerNorth americaNorth americanPivotal cohort